General Psychiatry
General Psychiatry RSS Feed RSS

Atypicals for Non-psychotic disorders

March 1, 2009
Heidi W. Ashih, MD, PhD
You may have noticed a recent torrent of FDA approvals and clinical trials for atypical antipsychotics in every disorder under the sun–except psychosis. Is this simply an effort by the sponsoring companies to get us to prescribe more antipsychotics? Or are these drugs truly effective for non-psychotic disorders? What’s the quality of the evidence?
Read More

Prescribing Atypical Antipsychotics: What are the Risks?

March 1, 2009
Michael Posternak, MD
Over the past several years, the use of antipsychotics has expanded dramatically. Aside from the traditional indication, schizophrenia, various members of this class have received FDA approval for bipolar mania, bipolar depression, major depression, and autism, and increasingly they are used off-label for anxiety, insomnia, and agitation.
Read More

Two New Meta-Analyses Compare Antidepressants

March 1, 2009
Glen Spielmans, PhD
Section editor, Glen Spielmans, PhD. Dr. Spielmans has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.
Two recent meta-analyses compared second-generation antidepressants (SGADs) to each other regarding efficacy and safety.
Read More
EXPERT Q&A

The Neurobiology of Schizophrenia

March 1, 2009
Fredrik Jarskog, MD

TCPR-March-2009-TCPR-Antipsychotic_Jarsog_headshot.png

Fredrik Jarskog, MD. Associate Professor of Clinical Psychiatry, Chief of Clinical Therapeutics Lieber Center for Schizophrenia Research and Treatment New York State Psychiatric Institute/Columbia University.

Dr. Jarskog has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity. Dr. Jarskog has disclosed that glycine, D-serine, D-cycloserine, and Glu2/3 receptor agonists are not FDA-approved for the treatment of schizophrenia.

Dr. Jarskog, for many years the dopamine theory of schizophrenia has been dominant in the field. What is the current status of that theory?
Read More

Risperidone Shows Mixed Results in Augmenting Antidepressant Treatment

February 1, 2009
Section editor, Glen Spielmans, PhD
A recent trial examined the impact of augmenting antidepressant treatment with risperidone. Participants had not shown a treatment response after taking an antidepressant for at least five weeks, and were then randomly assigned to receive either risperidone or placebo augmentation along with the same dose of their antidepressant.
Read More

Headache Is a Risk Factor For Suicidality

February 1, 2009
John O’Reardon, MD
The original Epidemiological Catchment Area (ECA) study (based on interviews conducted in the 1980s) examined the prevalence of mental disorders among adults in five American cities. Taking a fresh look, researchers examined data from 6,832 adults who resided in the community in order to ascertain the relationship between headache and suicidality.
Read More
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
Featured Video
Featured Podcast
Recommended

About

Shop Online

Newsletters

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.